GENE THERAPY FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

治疗晚期前列腺癌的基因疗法

• 批准号: 6219765
• 负责人: MITCHELL S. STEINER
• 金额: $ 1.63万
• 依托单位: UNIVERSITY OF TENNESSEE HEALTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-16 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6219765
• 关键词: antisense nucleic acid; clinical research; gene mutation; gene therapy; human subject; human therapy evaluation; neoplasm /cancer therapy; prostate neoplasms; transfection /expression vector

The focus of this proposal is to utilize noval corrective and cytoablative prostate specific viral based gene therapy to combat advanced prostate cancer. Corrective gene therapy attempts to correct genetic mutations in cancer by either repacing mutated genes with normal ones or suppressing overexpessed stimulatory oncogenes with antisense RNA viral vectors. In contrast, cytoablative gene therapy introduces prodrug enzymes (suicide genes) into cancer cells rendering them capable of activating innocuous agents into cancer-killing chemotherapeutic agents.

该提案的重点是利用新的纠正措施和细节性前列腺特异性病毒疗法来对抗晚期前列腺癌。 矫正基因治疗试图通过恢复正常基因的突变基因或用反义RNA病毒载体抑制过度表达的刺激性癌基因来纠正癌症中的基因突变。 相比之下，细节基因疗法将前药酶（自杀基因）引入癌细胞中，使它们能够将无害的剂激活为杀死癌症的化学治疗剂。